Summit Technology stock beams ahead 34.4% in July on anticipation of PRK approval.
This article was originally published in The Gray Sheet
Executive SummarySUMMIT STOCK ASCENDS 34.4% IN JULY on investor speculation that the firm's excimer laser system is nearing approval at FDA for photorefractive keratectomy (PRK). Stock in Summit Technology climbed 13 points during the month to close at 50-3/4.
You may also be interested in...
OIG will focus on successful drugs that have been repurposed as orphans, noting nine of the 10 top selling drugs have both orphan and non-orphan indications.
Switzerland’s SIX exchange-listed drug development company, Basilea, is moving two new oncology candidates along its R&D pipeline, supported by strong revenues from two partnered anti-infective products.
Recommendations from the Alliance for Regenerative Medicine aim to improve cross-border healthcare to ensure patients can access advanced therapies.